Angela Demichele, MD
Enriched profileMariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence; Director of Clinical/Translational Research in Solid Oncology · University of Pennsylvania
Angela Demichele is Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence; Director of Clinical/Translational Research in Solid Oncology at University of Pennsylvania. OpenAlex indexes 763 publications with 28,897 citations (h-index 90); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Angela Demichele, MD, is Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence at University of Pennsylvania, Perelman School of Medicine, Abramson Cancer Center. The public record shows 763 publications with 28,897 citations (h-index 90), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, PARP inhibition in cancer therapy. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 2 companies, 4 NIH-funded awards (1999–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Breast Cancer Treatment Studies
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 46 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 267.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 16 Oct 2026
2 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments
- PFIZER INC.Program year20231 payment
- Gilead Sciences, Inc.Program year20211 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor54.8%Anastrozole100%Part D<11 patientsKinase inhibitor45.2%Ibrance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
4 NIH research awards on record, funded 1999–2026 per NIH RePORTER. The latest:
- Project 1: Imaging, pathology, and molecular biomarkers to Optimize Treatment Switching within a SMART adaptive Framework
University of California, San Francisco
FY2026$301,145P01CA210961 - Project 1: Imaging, pathology, and molecular biomarkers to Optimize Treatment Switching within a SMART adaptive Framework
University of California, San Francisco
FY2025$300,575P01CA210961
Congress activity
Updated 16 Oct 2026
218 congress contributions (2004–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- ASPRIA: A single-arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple-negative breast cancer.
ASCO Annual Meeting
ASCO2026Co-author - Developing early endpoints in neoadjuvant breast cancer to support accelerated approval.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Mutability Dependence of Breast Cancer Metastasis and Latency to Recurrence.
Cancer discovery
Article2026 - Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
Science translational medicine
Article2026 - Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.
Nature communications
Article2025
Most-cited works
by citation count (OpenAlex)- 02Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerArticle1,268 citations2018
- 03
- 04
- 05Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast CancerArticle554 citations2016
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/angela-demichele-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
reachmd.com/profiles/angela-demichele-md-msce/LdgGv6/biography
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →reachmd.com ↗ - Other
breastcancer.org/bio/angela-demichele
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →breastcancer.org ↗ - Other
lbbc.org/about-us/medical-advisory-board/angela-demichele-md-msce
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lbbc.org ↗ - Other
pennmedicine.org/providers/profile/angela-demichele
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
- Co-Chair
ECOG/ACRIN Cooperative Group Breast Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Chair
Trial Operations Working Group, I-SPY Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Member
NCI Breast Cancer Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Chair-elect
ASCO Scientific Program Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
Nabila Dahodwala, MD
University of Pennsylvania
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles